Skip to main content
. 2024 Mar 26;14(1):54. doi: 10.1038/s41408-024-00996-x

Fig. 1. Kaplan Meier survival curves among the key subgroups of ALLG NBCR cohort. Log-rank statistics are used for comparisons.

Fig. 1

A Overall survival (OS) among all patients aged 18–59 years with FLT3-ITD and TKD mutated AML who received intensive chemotherapy, and according to the induction intensity (high or intermediate-dose cytarabine with anthracycline [H/IDAC + 3] versus standard 7 + 3). Missing induction regimen data for 1 patient. B OS and event-free survival (EFS) among patients aged 50–70 years with de novo AML who received intensive chemotherapy. Missing OS and EFS outcome data for 4 and 5 patients, respectively. C OS among patients aged 60–75 years with secondary or therapy-related AML who received intensive chemotherapy. Missing data for 2 patients. (D + E) OS (with 4-month landmark) among patients aged ≥55 years in first remission (CR1) according to (D) allogeneic HCT in CR1, and (E) number of consolidation chemotherapy received among patients (n = 185) not proceeding to HCT in CR1. F OS among patients who were unfit for intensive chemotherapy, according to the low-intensity regimens received.